HR+/HER2-先进的乳腺癌治疗在一线环境:专家评价
Katarzyna J Jerzak1, Nathaniel Bouganim2, Christine Brezden-Masley3
1Odette Cancer Centre, Sunnybrook Health Sciences, Toronto, ON M4N 3M5, Canada.
Current oncology (Toronto, Ont.)
|June 27, 2023
概括
CDK4/6抑制剂可以改善晚期HR+/HER2-乳腺癌的存活率. 本综述提供了加拿大第一线治疗的最佳实践建议,包括首选的CDK4/6抑制剂组合和特殊的人口考虑.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 循环素依赖性激酶4和6 (CDK4/6) 抑制剂已经改变了对激素受体阳性,人体表皮生长因子受体2-阴性 (HR+/HER2-) 先进乳腺癌的治疗.
- 不断扩大的证据基础需要明确的指导来实现最佳的临床应用.
研究的目的:
- 为加拿大HR+/HER2-晚期乳腺癌的第一线治疗提供基于证据的最佳实践建议.
- 针对不同患者群体的治疗策略,并概述监测和突变测试方法.
主要方法:
- 叙事综述综合了相关文献,临床指南和专家临床经验.
- 对临床试验数据的分析,支持CDK4/6抑制剂组合的整体生存率和无进展生存益处.
主要成果:
- 利博西克利布加上芳酶抑制剂推用于新发病或晚期复发的晚期疾病.
- 利博西克利布或阿贝马西克利布加富尔韦斯特兰特是早期复发的首选.
- 阿贝马西克利布或帕尔博西克利布作为替代品;内分泌治疗单独是特定禁忌的选择.
结论:
- 根据疾病表现和复发时间,建议使用特定的CDK4/6抑制剂组合.
- 针对特殊群体需要量身定制的方法,包括老年患者和患有内脏或转移性疾病的患者.
- 常规分子检测和多学科护理对于以患者为中心的管理至关重要.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.7K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K